)
Edge12 Dec 2025
Running on Clouds: The Story of On
The story of how a Swiss runner's pursuit of a new running sensation became On, aiming to be the most premium global sportswear brand worldwide.
Nxera Pharma
Nxera Pharma (4565) investor relations material
Nxera Pharma 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.44th Annual J.P. Morgan Healthcare Conference summary13 Jan, 2026
Strategic vision and business model
Focused on structure-based drug discovery using the NxWave platform, leveraging AI and proprietary data to deliver 30 drug candidates in 12 years.
Japanese commercial business modeled on U.S. go-to-market, targeting specialty and rare diseases with bilingual teams.
Aims for JPY 50 billion annual revenue and 30%+ operating margins by 2030, with launches from wave one before 2030 and wave two in 2030-2035.
Commercial business in Japan provides stable revenue, while U.K. research generates milestones and royalties.
Ongoing business development to add rare and specialty care products to the Japanese portfolio.
Commercial performance and product portfolio
PIVLAZ holds over 70% market share for aneurysmal subarachnoid hemorrhage in Japan, three and a half years post-launch.
QUVIVIQ, for insomnia, has seen sales accelerate after the two-week prescription limit was lifted.
Vamorolone, a next-generation corticosteroid for Duchenne muscular dystrophy, was recently in-licensed and will be rapidly advanced in Japan.
Vamorolone is expected to improve standard of care due to better safety and tolerability, with a potential launch in 2027 if Phase III is skipped, or 2029 otherwise.
Acquisition of Idorsia's Japan business and partnership with Shionogi have exceeded expectations, with both products now profitable.
R&D pipeline and partnering strategy
NxWave platform supports 15 clinical programs with partners across multiple therapeutic areas.
Portfolio refocused on high-potential oral small molecules for chronic weight management, obesity, and endocrine disorders.
Two Phase II-ready assets (GPR52 agonist for schizophrenia and EP4 agonist for IBD) are being prepared for competitive partnering.
Strong data for both assets, with GPR52 showing novel mechanism and EP4 demonstrating gut restriction and target engagement.
Track record of successful out-licensing and repartnering, with confidence in securing new deals.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Nxera Pharma earnings date
Q4 202513 Feb, 2026
Nxera Pharma
Next Nxera Pharma earnings date
Q4 202513 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Sosei Group Corporation, also known as Sosei Heptares, is a biopharmaceutical company that specializes in the development of drugs using its proprietary G protein-coupled receptor (GPCR) targeted StaR technology and structure-based drug discovery (SBDD) platform. The company's product lineup includes medicines such as Ultibro, Seebri, Enerzair, Breezhaler, Pivlaz, and Oravi. Sosei Group Corporation is headquartered in Chiyoda-ku, Tokyo, Japan, and its shares are listed on the Tokyo Stock Exchange.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage